StockNews.AI
HOWL
StockNews.AI
98 days

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

1. Sameer Chopra will present at the Cytokine Summit on May 15-16. 2. Presentation highlights validated clinical trial data for IL-2 and IL-12 therapies. 3. Werewolf's INDUKINE molecules selectively activate in tumor environments. 4. Company advances multiple product candidates for solid tumors and lymphoma.

4m saved
Insight
Article

FAQ

Why Bullish?

The presentation showcases significant advances in immunotherapy, potentially increasing investor confidence. Historical data shows similar announcements led to price rebounds.

How important is it?

The article discusses clinical validation and upcoming presentations, crucial for investor perception.

Why Short Term?

The impending presentation may drive immediate interest and market activity. Short-term responses to news events generally see direct impacts on stock prices.

Related Companies

BMYJNJREGN
May 13, 2025 08:00 ET  | Source: Werewolf Therapeutics, Inc. WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak during the Hanson Wade Cytokine-Based Drug Development Summit taking place May 15-16 in Boston, Massachusetts. The presentation will highlight how data from patients treated with IL-2 and IL-12 INDUKINE molecules in first-in-human clinical trials have successfully validated Werewolf’s unique approach to engineering differentiated, tumor-activated immunotherapies. Additional details are below. Topic: Tumor-activated INDUKINE Molecules: Improving the Therapeutic Index of Proinflammatory Cytokines for Cancer ImmunotherapyDate: Thursday, May 15, 2025Time: 4:15pm ET About Werewolf Therapeutics:Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com. Investor ContactDan FerryLifeSci Advisors617.430.7576daniel@lifesciadvisors.com Media Contact:Amanda SellersDeerfield Group301.332.5574amanda.sellers@deerfieldgroup.com Company Contact:Timothy TrostChief Financial OfficerWerewolf Therapeuticsttrost@werewolftx.com

Related News